Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04667585 · ClinicalTrials.gov registry record · NA
Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx
A NA study of Oropharynx Cancer, sponsored by Duke University.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT04667585: Recruiting NA study of Oropharynx Cancer, sponsored by Duke University.
NCT04667585 is a NA study of Oropharynx Cancer that is actively recruiting participants, run by Duke University. The registered enrollment target is 120 participants, roughly in line with the 127-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04667585, a NA study of Oropharynx Cancer, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to use intra-treatment 18FDG-PET/CT during definitive radiation therapy for human papillomavirus (HPV)-related oropharyngeal cancer (OPC) as an imaging biomarker to identify and select patients with a favorable response for chemoradiation dose de-escalation. This study will prospectively evaluate the clinical outcomes for patients undergoing dose de-escalation.
Primary Outcome
defined as the time between initiation of radiation treatment and the first documented recurrence of disease or death due to any cause as measured by medical record abstraction
Conditions Studied
Interventions
- RADIATION De-escalated radiation dose
- RADIATION Standard radiation dose
- OTHER 18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)
Study Locations (2)
North Carolina
- Duke University Medical Center - Durham
- Duke Raleigh Hospital - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-04-12 |
| Est. Completion | 2028-01 |
| Phase | NA |
What NCT04667585 shows while recruiting
NCT04667585 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 127-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target.
The record links to 1 condition, with Oropharynx Cancer appearing as the primary indexed condition, and to 3 interventions - of which De-escalated radiation dose is the first listed.
NCT04667585 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04667585 about?
NCT04667585 is a clinical study titled "Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx". The purpose of this study is to use intra-treatment 18FDG-PET/CT during definitive radiation therapy for human papillomavirus (HPV)-related oropharyngeal cancer (OPC) as an imaging biomarker to identify and select patients with a favorable response for chemoradiation dose de-escalation. This study w...
What is the current status of trial NCT04667585?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2021-04-12. Estimated completion is 2028-01.
What conditions does trial NCT04667585 study?
This clinical trial studies the following conditions: Oropharynx Cancer.
What interventions are being tested in trial NCT04667585?
The interventions under investigation include: De-escalated radiation dose (RADIATION), Standard radiation dose (RADIATION), 18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT) (OTHER).
Who is sponsoring clinical trial NCT04667585?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04667585 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharynx Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04667585's enrollment target sits among peer trials
120 5th of 26 higher than 22 of 26 other Oropharynx Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oropharynx Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
RECRUITING · NA
-
Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly
RECRUITING · NA
-
De-escalation of Adjuvant Radiation for Low-Risk HPV Oropharyngeal Cancers
RECRUITING · NA
-
The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors
ACTIVE NOT RECRUITING · NA
-
Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer
COMPLETED · NA
-
Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI